For instance, various publications disagree over the cell cycle stage affected by MELK inhibition (Du et al., 2014; Kig et al., 2013; Alachkar et al., 2014; Wang et al., 2014; Beke et al., 2015), while other publications disagree over whether receptor-positive breast cancer cell lines are sensitive (Lin et al., 2007; Beke et al., 2015; Chung et al., 2012) or resistant (Wang et al., 2014) to MELK inhibition. The gene discussed is MELK; the disease is breast carcinoma.